Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib biomarker study in idiopathic pulmonary fibrosis with limited FVC impairment
2015-003148-38Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nintedanib in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Rate of change in blood CRPM from baseline to week 12. Started Mar 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2015-003148-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003148-38.